Bio-Techne names successor general counsel
Shane Bohnen is being promoted to become senior vice president and general counsel at Bio-Techne Corporation on March 3.
He will succeed Brenda Furlow, who is retiring from the company having been executive vice president and general counsel for the past nine years. Furlow has provided and will continue to provide transition support until her retirement on March 3 and will work in a consulting capacity for special projects in the future.
Bohnen has been Bio-Techne’s associate general counsel since joining the company in 2019. During his time with the company he has led initiatives such as commercial support across the Bio-Techne enterprise, co-leading recent M&A activities, contributing to the company’s ESG efforts, including its most recent corporate sustainability report, and litigation.
He was previously in-house corporate counsel at Smiths Medical, where he held roles of increasing seniority including providing global legal support across five enterprises. Before that, he spent 10 years in private practice working in life sciences and related litigation.
Furlow joined Bio-Techne as senior vice president and general counsel in August 2014. She was previously affiliated with AlphaTech Counsel and was general counsel to emerging growth technology companies. Between 2007 and 2011 she was general counsel for TomoTherapy. From 1998 to 2007 she was general counsel for Promega Corporation, a global life sciences company.
Chuck Kummeth, president and CEO of Bio-Techne, says in a statement: ‘I want to personally thank Brenda for her leadership and significant contributions over the last nine years at Bio-Techne. She established the legal and compliance functions at Bio-Techne, and most recently has been instrumental in leading our corporate sustainability program. Her legal advice and strategic insight have played an integral role in the company’s success, and I wish her the best in the future.
‘Shane has been a trusted legal adviser to the Bio-Techne executive team since joining the company in 2019. His in-depth knowledge of Bio-Techne and experience in our complex commercial business, management of legal and regulatory risk, oversight of compliance and ethics programs and corporate governance experience will be essential as we continue to execute our long-term growth strategy.’